Q1: What is Obesema 0.5mg Injection and what does it do
GLP-1 receptor signaling in the ventral tegmental area and nucleus accumbenstwo key reward centerscan modulate dopamine release and blunt the salience of addictive stimuli
For patients on GLP-1 receptor agonists, regular monitoring should include HbA1c, weight, blood pressure, and lipid profiles to assess overall metabolic improvements
Photo by Unsplash Studies have shown that glutathione may lighten skin, but results vary
In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight